Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives

Business Wire February 27, 2023

Amarin to Present at Cowen's 43rd Annual Health Care Conference

GlobeNewswire February 22, 2023

Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change

Business Wire February 21, 2023

Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023

GlobeNewswire February 21, 2023

Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change

Business Wire February 20, 2023

Amarin Urges Shareholders to Vote "Against" Sarissa's Harmful Proposals at Upcoming General Meeting - IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

GlobeNewswire February 17, 2023

Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders

Business Wire February 17, 2023

Sarissa Capital Blasts Amarin's Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board

Business Wire February 16, 2023

Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote "AGAINST" Sarissa's Value-Destructive Proposals

GlobeNewswire February 16, 2023

Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards

GlobeNewswire February 16, 2023

Sarissa Capital Uncovers That Amarin's Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So

Business Wire February 15, 2023

Sarissa Capital Disappointed That Amarin Webcast Continues Board's Defense of Poor Results and Lack of Accountability

Business Wire February 14, 2023

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote "AGAINST" All of Sarissa's Proposals

GlobeNewswire February 13, 2023

Amarin Shareholders Invited to Webcast with Board and Management Team

GlobeNewswire February 13, 2023

Sarissa Capital Warns of Amarin's Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards

Business Wire February 13, 2023

Sarissa Capital Does Not Believe Amarin Cares About Shareholders

Business Wire February 9, 2023

Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card "AGAINST" Sarissa's Harmful Proposals

GlobeNewswire February 9, 2023

Sarissa Capital Highlights Amarin's Inaccurate and Misleading Statements

Business Wire February 7, 2023

Amarin Mails Letter to Shareholders Highlighting Sarissa's Myths vs. The Facts

GlobeNewswire February 6, 2023

Sarissa Capital Highlights Amarin's Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin

Business Wire February 3, 2023